Abzena Bristol - Hero

Oncology CDMO + CRO Development & Manufacturing Services

Oncology development is moving faster than ever. Partner with an integrated CDMO + CRO with HPAPI handling expertise, that removes complexity, reduces risk, and helps you move life-changing therapies forward with confidence faster.

Accelerate your oncology biologics program with a proven integrated CDMO + CRO that simplifies development through manufacturing.

Abzena - 25+ Years of Bioconjugation Expertise

25+ Years of Expertise

Extensive experience in support of oncology innovators with integrated HPAPI handling, complex bioconjugation, & manufacturing solutions.

Abzena - 400+ ADCs Produced

400+ ADCs Produced Globally

Supporting lead selection, optimization, bioconjugation & development of targeted oncology therapeutics.

Abzena - 14+ Bioconjugates in Clinic

14+ Bioconjugates in Clinic

Including oncology-focused bioconjugate programs across multiple modalities.

Abzena - 2,000+ Conjugates Developed

2,000+ Conjugates Developed

Delivering expertise across ADCs, AOCs, RDCs, & other next-generation therapeutic formats.

Cancer treatment is being transformed by innovative therapeutic modalities that combine precision targeting with potent therapeutic activity, such as antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs). Abzena helps developers accelerate oncology programs through integrated discovery, development, and manufacturing capabilities that progress complex biologics from proof of concept to clinical manufacturing and beyond.

Abzena has more than 25 years of bioconjugation experience with state-of-the art high-potency (HPAPI) facilities, and we’ve supported the development of thousands of conjugates, including more than 400 ADCs. Our integrated approach helps sponsors engineer quality, stability, scalability, and manufacturability into oncology programs from the earliest stages of development.

Partnering with Abzena, your oncology program will benefit from;

  • Access to Genuine Scientific & Technical Experts
  • Proactive Solutions for Streamlining Development
  • Diverse and Interconnected Teams
  • End-to-End Support Under One Organization

From antibody discovery and developability assessment through GMP-ready cell line development, process development, analytical testing, and cGMP manufacturing, Abzena provides integrated program support under one CDMO + CRO. This integrated approach helps streamline decision-making, reduce development risk, and accelerate timelines for oncology innovators.

Contact Our Experts Move forward from DNA to IND/CTA faster

Expertise Across Emerging Oncology Modalities

Bioconjugates are creating new and more effective treatment options for patients, particularly in oncology. Abzena supports ADCs, bispecific ADCs, dual-payload ADCs, antibody-oligonucleotide conjugates (AOCs), and radiopharmaceutical conjugates (RDCs), alongside other innovative modalities, helping innovators overcome development complexity and accelerate clinical success.

Antibody-Drug Conjugates (ADCs)

ADCs have become one of the most powerful modalities in targeted oncology, delivering potent therapies directly to cancer cells while minimizing damage to healthy tissue. Abzena provides end-to-end ADC development and manufacturing solutions spanning antibody optimization, linker-payload design, bioconjugation, analytical development, and GMP manufacturing.

Key strengths include:

  • 400+ ADCs produced globally.
  • Proprietary ThioBridge® conjugation technology for precise, site-specific conjugation and enhanced stability.
  • Early de-risking and optimization to improve the likelihood of clinical success.
Discover ADC Expertise

Antibody-Oligonucleotide Conjugates (AOCs)

In oncology, AOCs offer the potential to directly target cancer-driving genes while reducing off-target effects through antibody-mediated delivery. By combining the specificity of antibodies with technologies such as siRNA and antisense oligonucleotides, AOCs create new opportunities to address disease mechanisms that may be difficult to reach with conventional therapeutics.

Key strengths include:

  • End-to-end AOC development from design to GMP manufacture.
  • 20+ years of bioconjugation expertise across antibodies and oligos.
  • Scalable manufacturing and analytics for clinical-ready AOCs.
Discover AOC Expertise

Degrader-Antibody Conjugates (DACs)

Degrader-Antibody Conjugates (DACs) represent an emerging class of targeted therapeutics that combine the selectivity of antibodies with the promise of targeted protein degradation. As oncology innovators explore new approaches to selectively eliminate disease-driving proteins, DACs are increasingly being investigated as a next-generation bioconjugate modality.

Key strengths include:

  • Extensive experience in antibody conjugation and complex biotherapeutics.
  • Advanced linker & payload design that optimizes degrader delivery, stability, and efficacy.
  • Supports progression from discovery through GMP production.
Discover DAC Expertise

Bispecifics & T Cell Engagers (TCEs)

TCEs represent a new generation of antibody-based immunotherapies designed to redirect immune cells to selectively destroy cancer cells. Abzena’s expertise in bispecifics and multispecifics, molecular engineering, and platform-based development strategies helps developers create safer, scalable, and clinically viable immunotherapy candidates.

Key strengths include:

  • Deep bispecific design expertise across multiple formats.
  • Data-led molecular engineering for optimized TCE design.
  • Integrated development and manufacturing from discovery to clinic.
Discover Bispecific Expertise

Designed Around One Goal: Better Outcomes for Patients

Abzena’s mission is to help partners realize the full potential of their molecules and move medicines forward faster. By combining scientific expertise, innovative technologies, and integrated development capabilities, Abzena supports the advancement of new and emerging oncology treatments that have the potential to improve patients’ lives.

Discover our case studies on oncology program success to learn why Abzena could be the right partner for your program.

Case Study 1: Complex Biologics Development for a Bispecific Fusion Nanobody

A clinical-stage life sciences company developing conditionally acting medicines for cancer partnered with Abzena to advance a VHH camelid nanobody with cytokine fusion. Using the AbZelectPRO™ cell line development platform, Abzena delivered a highly stable, high-producing cell line for the bispecific oncology program within a fully integrated development environment.

Key Outcomes

  • Stable, high-producing cell line generated for a complex oncology biologic
  • Streamlined development through a single integrated partner
Read Case Study

Case Study 2: Anti-PD1 Antibody Discovery Program

Through its B Cell discovery platform, Abzena supported an Anti-PD1 antibody discovery program designed to accelerate candidate identification. The approach delivered reduced timelines and earlier access to high-quality characterization data, enabling the generation of a diverse panel of recombinant antibodies for further development.

Key Outcomes

  • Faster discovery timelines
  • Earlier decision-making through improved candidate characterization
Read Case Study

Case Study 3: Advancing ADC Development Through Mechanistic Understanding

Working with Sartorius, Abzena demonstrated how integrated live-cell imaging can provide deeper insight into ADC mechanisms of action. Using clinically validated ADCs as benchmarks, the team generated kinetic data that revealed important mechanistic differences and supported more informed candidate selection decisions.

Key Outcomes

  • Improved understanding of ADC pharmacology
  • Enhanced early-stage candidate selection and program de-risking
Read Case Study

Case Study 4: ThioBridge® Technology for Next-Generation ADCs

Abzena’s proprietary ThioBridge® platform has been used to support ADC programs transitioning from preclinical development into clinical manufacturing. The case study demonstrates how the technology helps improve conjugate stability, potency, and scalability while supporting successful process scale-up.

Key Outcomes

  • Improved ADC stability and efficacy
  • Successful progression from toxicology studies to clinical-scale manufacture
Read Case Study

Customer Success Spotlight

GMP Manufacturing Suite - Abzena

Abzena’s customers continue to accelerate innovative oncology programs forward. Recent examples of their success include:

"Thank you to the team at Abzena for being an exceptional CRO that provides reliable, high quality data and expertise. Combining humanization with  the Abzena Human Composite Antibody  (CHAb™) platform with rigorous EpiScreen® immunogenicity profiling and Cytokine Release Assay has given us a highly differentiated asset as we advance toward IND-enabling studies."

Syed Karim MD 
Tasrif Pharmaceuticals

What sets our oncology biologics CDMO +CRO services and solutions apart?

  • Deep Expertise in Complex Oncology Modalities: Abzena has built its capabilities around the modalities that are shaping the future of oncology.
  • End-to-end Support: From discovery to preclinical IND/CTA enabling through commercialization, Abzena has the expertise and facilities to deliver your life-changing oncology therapeutic.
  • Scientific Expertise: Unparalleled depth across complex biologics and bioconjugates.
  • Innovative Platform Technologies: Proven to accelerate programs, these include ThioBridge®, CHAb™, AbZelectPRO™, and EpiScreen® 2.0.
  • Integrated Scientific Teams: Abzena is always focused on accelerating programs while minimizing downstream development risk.
  • Proven Success with Oncology Innovators: Abzena’s expertise is reflected in the recent success of its customers such as Promatix, Tasrif Pharmaceutical and Orion.

Enabling Services

Abzena’s genuine scientific and technical experts will focus and collaborate with you on streamlining your oncology development and manufacturing programs proactively. We de-risk and challenge outdated assumptions to do what is best for your oncology program to move forwards.

Linker Payload Design & Synthesis

Supporting your candidate ranking and lead selection process, we determine the optimal design of linker payload architecture and profiling in a series of in silico, ...

Learn More

Bioconjugate Discovery & Design

We deliver tailored solutions for small molecule intermediates including high potency chemistry, payloads, linkers, and bioconjugates.

Learn More

Immunogenicity Assays

Leverage our experience in delivering immunogenicity assays that help you better understand your bioconjugate or ADC earlier.

Learn More

Cell Line Development

Achieve stable pools in 3 weeks, accelerate from DNA to RCB in just 10 weeks and GMP in 6 months with our industry-leading mammalian cell line development services.

Learn More

Technology Transfer

We utilize a comprehensive risk-based approach to ensure a successful technology transfer by capturing process knowledge throughout your program and incorporating any regulatory authority feedback ...

Learn More

Formulation Development

With a focus on aligning your drug candidates to the ideal target product profile (TPP) we develop a comprehensive range of formulation development packages.

Learn More

Process Development & Optimization

Seamless upstream and downstream biologics process development, optimization and cGMP manufacturing from cell line development (CLD) to patient.

Learn More

Highly Potent API (HPAPI) Development & Manufacturing

Utilizing a combination of technology, infrastructure, and expertise, we provide you with seamless, flexible highly potent API development and manufacturing tailored to your specific needs.

Learn More

Clinical Manufacturing

Our integrated network of technical, quality, regulatory, and program management supports the delivery of your commercial manufacturing program. We offer reliable, predictable performance under cGMP ...

Learn More

Latest News & Insight

Articles

PharmaCircle: Analytical Q&A on methods for Bispecific Antibodies

Read More

Blog

Engineering AOC Manufacturability from the Start

Read More

Blog

Getting Bispecific Antibody Release Testing Right

Read More

Oncology Drug Development & Manufacturing FAQs

What should oncology companies look for in a cGMP manufacturing partner?

The best oncology-focused cGMP manufacturing organizations combine discovery, development, analytical testing, process development, and GMP manufacturing under one integrated model. This helps reduce development risk, streamline technology transfer, and accelerate timelines for complex biologics and bioconjugates.

Does Abzena manufacture oncology biologics and bioconjugates?

Yes. Abzena supports the development and cGMP manufacturing of multiple oncology modalities, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), radionuclide drug conjugates (RDCs), bispecific antibodies, and degrader-antibody conjugates (DACs).

What experience does Abzena have with oncology-focused ADC development?

Abzena has more than 25 years of bioconjugation experience, has developed over 2,000 conjugates, produced more than 400 ADCs, and scaled up more than 50 bioconjugation programs. The company provides integrated ADC development and manufacturing services from antibody and linker-payload design through clinical and commercial manufacture.

How does Abzena help reduce risk in oncology drug development?

Abzena applies a developability-focused approach that evaluates candidate specificity, functionality, safety, manufacturability, and scalability early in development. This helps identify and mitigate potential issues before they become costly manufacturing or clinical challenges.

Can Abzena support emerging oncology modalities beyond traditional antibodies?

Yes. Abzena supports next-generation oncology therapeutics including ADCs, AOCs, RDCs, DACs, bispecific antibodies, multispecific antibodies, and other complex bioconjugates. Its integrated scientific and manufacturing capabilities are designed to help developers advance innovative therapies from discovery through clinical and commercial production.

Why Choose Abzena for Oncology Biologics?

Oncology therapeutics are becoming increasingly complex, requiring expertise that spans discovery, developability, bioconjugation, analytical sciences, process development, and manufacturing. With more than 20 years of experience supporting biologics and bioconjugates, proprietary platform technologies, and a fully integrated development model, Abzena helps oncology innovators reduce risk, accelerate timelines, and advance next-generation therapies from concept to clinic and beyond.